References
- Rasquin LI, Anastasopoulou C, Mayrin JV. Polycystic Ovarian Disease. 2022 Nov 15. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan.
- Teede HJ, Misso ML, Costello MF, et al. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018, 110(3):364-379.
- Speiser PW, Arlt W, Auchus RJ, et al. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 2018, 103(11):4043-4088.
- Sam S. Obesity and Polycystic Ovary Syndrome. Obes Manag, 2007, 3(2):69-73.
- Tsenkova P, Robeva R, Elenkova A, Zacharieva S. Prevalence and characteristics of the polycystic ovarian syndrome in overweight and obese premenopausal women. Acta Endocrinol (Buchar), 2022, 18(4):417-423.
- Falhammar H, Frisén L, Hirschberg AL, et al. Increased Cardiovascular and Metabolic Morbidity in Patients With 21-Hydroxylase Deficiency: A Swedish Population-Based National Cohort Study. J Clin Endocrinol Metab, 2015, 100(9), 3520-3528.
- Brandfon S, Eylon A, Khanna D, Parmar MS. Advances in Anti-obesity pharmacotherapy: current treatments, emerging therapies, and challenges. Cureus, 2023; 15(10):e46623.
- Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metabol, 2004, 287:E199-E206.
- Rowlands J, Heng J, Newsholme P, Carlessi R. Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function. Front Endocrinol (Lausanne), 2018, 9:672.
- Lin T, Li S, Xu H, et al. Gastrointestinal hormone secretion in women with polycystic ovary syndrome: an observational study. Hum Reprod, 2015, 30(11):2639-2644.
- Aydin K, Arusoglu G, Koksal G, et al. Fasting and post-prandial glucagon like peptide 1 and oral contraception in polycystic ovary syndrome. Clin Endocrinol (Oxf), 2014, 81(4):588-592.
- Robeva R, Elenkova A, Kirilov G, Zacharieva S. Plasma-free metanephrines, nerve growth factor, and renalase signifi-cance in patients with PCOS. Endocrine. 2023;81(3):602-612.
- Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care, 2004, 27(6):1487-1495.
- Gama R, Norris F, Wright J, et al. The entero-insular axis in polycystic ovarian syndrome. Ann Clin Biochem, 1996, 33 (Pt 3):190-195.
- Vrbikova J, Hill M, Bendlova B, et al. Incretin levels in polycystic ovary syndrome. Eur J Endocrinol, 2008, 159(2):121-127.
- Cassar S, Teede HJ, Harrison CL, et al. Biomarkers and insulin sensitivity in women with Polycystic Ovary Syndrome: Characteristics and predictive capacity. Clin Endocrinol (Oxf), 2015, 83(1):50-58.
- Glintborg D, Mumm H, Holst JJ, Andersen M. Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndrome. Endocr Connect, 2017, 6(4):267-277.
- Pontikis C, Yavropoulou MP, Toulis KA, et al. The incretin effect and secretion in obese and lean women with polycystic ovary syndrome: a pilot study. J Womens Health (Larchmt), 2011, 20(6):971-976.
- Ferjan S, Jensterle M, Oblak T et al. An impaired glucagon-like peptide-1 response is associated with prediabetes in polycystic ovary syndrome with obesity. J Int Med Res, 2019, 47(10):4691-4700.
- Svendsen PF, Nilas L, Madsbad S, Holst JJ. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin. Metabolism, 2009, 58(5):586-593.
- Stinson SE, Jonsson AE, Lund MAV, et al. Fasting Plasma GLP-1 Is Associated with Overweight/Obesity and Cardio-metabolic Risk Factors in Children and Adolescents. J Clin Endocrinol Metab, 2021, 106(6):1718-1727.
- Vilsbøll T, Krarup T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab, 2003, 88(6):2706-2713.
- Chia CW, Carlson OD, Liu DD, et al. Incretin secretion in humans is under the influence of cannabinoid receptors. Am J Physiol Endocrinol Metab, 2017, 313(3):E359-E366.
- Dybjer E, Engström G, Helmer C, et al. Incretin hormones, insulin, glucagon and advanced glycation end products in relation to cognitive function in older people with and without diabetes, a population-based study. Diabet Med, 2020, 37(7):1157-1166.
- Kubota S, Yabe D. Elevation of Fasting GLP-1 Levels in Child and Adolescent Obesity: Friend or Foe? J Clin Endocrinol Metab, 2021, 106(9):e3778-e3780.
- Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes, 2008, 57(5):1340-1348.
- Ejarque M, Guerrero-Pérez F, de la Morena N, et al. Role of adipose tissue GLP-1R expression in metabolic improvement after bariatric surgery in patients with type 2 diabetes. Sci Rep, 2019, 9(1):6274.
- Pugliese G, de Alteriis G, Muscogiuri G, et al. Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? J Endocrinol Invest, 2023, 46(9):1761-1774.
- Pall M, Azziz R, Beires J, Pignatelli D. The phenotype of hirsute women: a comparison of polycystic ovary syndrome and 21-hydroxylase-deficient nonclassic adrenal hyperplasia. Fertil Steril, 2010, 94(2):684-689.
- Auchus RJ, Arlt W. Approach to the patient: the adult with congenital adrenal hyperplasia. J Clin Endocrinol Metab, 2013, 98(7):2645-2655.
- Nordenström A, Lajic S, Falhammar H. Long-Term Outcomes of Congenital Adrenal Hyperplasia. Endocrinol Metab (Seoul), 2022, 37(4):587-598.
- Sato T, Hayashi H, Hiratsuka M, Hirasawa N. Glucocorticoids decrease the production of glucagon-like peptide-1 at the transcriptional level in intestinal L-cells. Mol Cell Endocrinol, 2015, 406:60-67.
- Kappe C, Fransson L, Wolbert P, Ortsäter H. Glucocorticoids suppress GLP-1 secretion: possible contribution to their diabetogenic effects. Clin Sci (Lond), 2015, 129(5):405-414.
- Lu Y, Wang E, Chen Y, et al. Obesity-induced excess of 17-hydroxyprogesterone promotes hyperglycemia through activation of glucocorticoid receptor. J Clin Invest, 2020, 130(7):3791-3804.
- Turcu AF, Auchus RJ. Clinical significance of 11-oxygenated androgens. Curr Opin Endocrinol Diabetes Obes, 2017, 24(3):252-259.
- Turcu AF, Nanba AT, Chomic R, et al. Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency. Eur J Endocrinol, 2016, 174(5):601-609.
- Yoshida T, Matsuzaki T, Miyado M, et al. 11-oxygenated C19 steroids as circulating androgens in women with polycystic ovary syndrome. Endocr J, 2018, 65(10):979-990.
- Auer MK, Hawley JM, Lottspeich C, et al. 11-Oxygenated androgens are not secreted by the human ovary: in-vivo data from four different cases of hyperandrogenism. Eur J Endocrinol, 2022, 187(6):K47-K53.
- O’Reilly MW, Kempegowda P, Jenkinson C, et al. 11-Oxygenated C19 Steroids Are the Predominant Androgens in Polycystic Ovary Syndrome. J Clin Endocrinol Metab, 2017, 102(3):840-848.